Articles from Virpax Pharmaceuticals

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQVRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that Gerald W. Bruce, CEO, will present and host one-on-one meetings with investors at the Sidoti August Virtual Investor Conference, taking place on August 14-15, 2024. Joining him will be Vinay Shah, CFO.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQVRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, announced today that it has received formal notice from the Listing Qualifications staff of The Nasdaq Stock Market LLC indicating that Virpax has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQVRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced results for a Swine Model pilot study for Probudur, Virpax’s long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate and extended pain relief.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQVRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it will be presenting at the upcoming Bio International Convention in San Diego on Monday, June 3rd at 4:00 p.m. PT. Gerald W. Bruce, CEO of Virpax, will deliver the corporate presentation.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQVRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced results for a Maximum Tolerated Dose (MTD) study in Sprague-Dawley Rats for Probudur™.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQVRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barriers, today announced that it received a notice (the “Notice”) from the Listing Qualifications Staff of the Nasdaq Stock Market (“Nasdaq”) on November 16, 2023 stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended, September 30, 2023 (the “Quarterly Report”) with the Securities and Exchange Commission.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQVRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it expects to submit an Investigational New Drug Application (IND) for Envelta in mid-2024 following review of comments made by the US Food and Drug Administration on the Company’s Pre-IND submission. If successful, that would allow clinical trials to begin by the middle of 2024.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQVRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, announced today that Gerald W. Bruce has been appointed as President and CEO of Novvae™ Pharmaceuticals, Virpax’s wholly-owned subsidiary focused solely on advancing the Company’s OTC pipeline.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQVRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has formed a new wholly-owned subsidiary, Novvae™ Pharmaceuticals, Inc. (Novvae), which has been established to focus exclusively on advancing Virpax’s OTC pipeline.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQVRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has received a ruling on the lawsuit filed by Scilex Pharmaceuticals NASDAQ:SCLXNASDAQSCLX)

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQVRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has filed a new provisional patent application with the United States Patent and Trademark Office (‘USPTO’) entitled “Intranasal Delivery” related to its Envelta™ product candidate.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQVRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that effective June 20, 2023, the Board of Directors of Virpax Pharmaceuticals, Inc. appointed Vinay Shah to serve as the Company’s Chief Financial Officer. As Chief Financial Officer, Mr. Shah will also serve as the Company’s principal financial officer and principal accounting officer.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQVRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced recent progress made in its Envelta development program. Envelta is the Company’s non-opioid pain product candidate for acute and chronic pain that is being funded under an in-kind grant from the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQVRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, announced today that the Company has appointed Barbara A. Ruskin, Ph.D, J.D. to its Board of Directors, increasing the size of the Board to nine members.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQVRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, announced today that the Company has completed FDA required preclinical toxicology studies for its licensed Molecular Envelope Technology (MET). MET enhances the delivery of Virpax’s non-addictive pain product and its epilepsy product candidate. MET is also utilized in the Company’s viral barrier product candidate. These preclinical toxicology studies were performed to evaluate the safety of the MET platform and to support the IND submission of each product candidate.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQVRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral indications, today announced it will pursue an OTC Intranasal Medical Device Consumer regulatory pathway for AnQlar™, the Company’s product candidate being developed as a prophylactic antiviral barrier against influenza and SARS-CoV-2.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQVRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral indications, today announced that it will pursue a direct to OTC regulatory pathway for Epoladerm™, the Company’s product candidate to treat pain associated with osteoarthritis.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQVRPX), today announced it will present a poster on Leucine Enkephalin as a potential analgesic at PAINWeek 2021, being held on September 7-11, 2021 at The Cosmopolitan in Las Vegas, NV.

Virpax® Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQVRPX), a company specializing in developing pharmaceutical product candidates for pain management, today announced the appointment of Gerald W. Bruce and Michael F. Dubin, CPA to its Board of Directors.

Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQVRPX), today announced that the Investigational New Drug (IND) Application enabling studies for Envelta™ being performed under a Cooperative Research and Development Agreement (CRADA) entered into by Virpax and the National Center for Advancing Translational Sciences (NCATS) for chronic pain, will also be used as a source for INDs for two additional indications, for cancer pain and Post-Traumatic Stress Disorder (PTSD). NCATS has commenced the IND enabling studies of Envelta to support Virpax’s future application for clearance from the Food and Drug Administration (FDA) to initiate Virpax’s first-in-human clinical trials.